Anti-IgE therapy (such as Xolair/Omalizumab) can block the ability of circulating IgE to bind with histamine releasing mast cells, reducing the allergic response. Omalizumab has been approved in the UK for patients from the age of 6 years with severe, persistent allergic asthma, uncontrollable with oral or injectable corticosteroids.

​

Anti-IgE treatment has also been approved for chronic spontaneous urticaria (chronic hives) in patients over 12 years of age in whom antihistamines are ineffective.           

​

Our Consultants at the LAC have experience of treating patients with this type of medication.​